Inflammatory Risk Observed in Nearly 40% of Patients with HF

Why It Matters

Identifying a sizable, consistent inflammatory cohort across heart‑failure phenotypes creates a clear target for emerging therapies, potentially reducing morbidity and healthcare costs associated with residual cardiovascular risk.

Key Takeaways

• High inflammatory risk (hsCRP ≥2 mg/L) found in ~38% of HF patients.
• Risk consistent across HFpEF, HFmrEF, and HFrEF subtypes.
• Obesity, CKD, smoking, and dyslipidemia predict elevated hsCRP.
• Women and advanced NYHA class patients show higher prevalence.
• Supports anti‑inflammatory therapy development for heart‑failure management.

Pulse Analysis

Inflammation has long been recognized as a driver of atherosclerotic events, but its role in heart‑failure (HF) has been less clear. The POSEIDON real‑world study, presented at the European Atherosclerosis Society Congress, quantifies this gap by showing that nearly two‑in‑five HF patients across 18 countries carry a high‑risk inflammatory signature (hsCRP ≥ 2 mg/L). This prevalence is strikingly consistent across the entire ejection‑fraction spectrum, suggesting that inflammation is not a peripheral phenomenon limited to a specific HF phenotype but a core component of disease biology.

The analysis also delineates a cardio‑kidney‑metabolic (CKM) phenotype that predicts elevated hsCRP. Factors such as obesity, reduced glomerular filtration rate, smoking, dyslipidemia, and prior autoimmune conditions emerge as independent predictors, while women and patients with higher NYHA class display amplified risk. Notably, body‑mass index correlates with inflammation only in HFpEF, hinting at subtype‑specific pathophysiology. These insights enable clinicians to stratify patients more precisely, integrating inflammatory biomarkers into existing risk models and potentially guiding personalized therapeutic decisions.

From a market perspective, the data provide a compelling rationale for anti‑inflammatory drug development in HF. Pharmaceutical pipelines that target interleukin‑6, NLRP3 inflammasome, or broader cytokine pathways can now justify larger, phenotype‑driven trials, leveraging hsCRP as a selection criterion. If successful, such agents could fill a therapeutic void, reducing hospitalizations and improving quality of life for millions of HF patients, while delivering significant commercial upside for innovators. The convergence of epidemiologic evidence and mechanistic plausibility positions inflammation as the next frontier in heart‑failure care.